Brown, Lisle/Cummings, Inc. Sangamo Therapeutics, Inc Transaction History
Brown, Lisle/Cummings, Inc.
- $329 Billion
- Q3 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 1,525 shares of SGMO stock, worth $2,867. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,525
Previous 1,525
-0.0%
Holding current value
$2,867
Previous $546,000
141.94%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SGMO
# of Institutions
115Shares Held
56.4MCall Options Held
576KPut Options Held
1.17M-
Wasatch Advisors Inc Salt Lake City, UT19.4MShares$36.6 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.6MShares$18 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.85MShares$9.12 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$8.84 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.35MShares$4.43 Million0.0% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $294M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...